Drug‐specific CD4 + T‐cell immune responses are responsible for antituberculosis drug‐induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome

2016 ◽  
Vol 176 (2) ◽  
pp. 378-386 ◽  
Author(s):  
Y.‐M. Ye ◽  
G.‐Y. Hur ◽  
S.‐H. Kim ◽  
G.‐Y. Ban ◽  
Y.‐K. Jee ◽  
...  
Keyword(s):  
Drug Reaction ◽  
T Cell ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
T Cell Immune Responses ◽  
Systemic Symptoms ◽  
Maculopapular Exanthema

scholarly journals NKT Cell-Dependent Regulation of Secondary Antigen-Specific, Conventional CD4+ T Cell Immune Responses

2010 ◽  
Vol 184 (10) ◽  
pp. 5589-5594 ◽  
Author(s):  
YoungHyun Shin ◽  
Changwan Hong ◽  
Hyunji Lee ◽  
Jung Hoon Shin ◽  
Seokmann Hong ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Nkt Cell ◽  
T Cell Immune Responses

scholarly journals Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort

2014 ◽  
Vol 162 (2) ◽  
pp. 264-272 ◽  
Author(s):  
Rose Nabatanzi ◽  
Lois Bayigga ◽  
Isaac Ssinabulya ◽  
Agnes Kiragga ◽  
Andrew Kambugu ◽  
...  
Keyword(s):  
T Cell ◽  
Antiretroviral Therapy ◽  
Immune Responses ◽  
Cd4 T Cell ◽  
Cd4 Counts ◽  
T Cell Immune Responses

scholarly journals Morphologic Spectrum of Lymphadenopathy in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome

2021 ◽  
Author(s):  
Hui-Chun Chen ◽  
Ren Ching Wang ◽  
Huey-Pin Tsai ◽  
L. Jeffrey Medeiros ◽  
Kung-Chao Chang
Keyword(s):  
Differential Diagnosis ◽  
Drug Reaction ◽  
T Cell ◽  
Drug Exposure ◽  
Case Series ◽  
Reactive Lymphoid Hyperplasia ◽  
Drug Induced ◽  
Pathologic Findings ◽  
Necrotizing Lymphadenitis ◽  
Systemic Symptoms

Context.— Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DRESS) is a drug-induced, adverse T-cell–mediated hypersensitivity reaction that most often involves skin. The pathologic findings of DRESS-related lymphadenopathy have been described infrequently in the literature. Objective.— To present a case series of DRESS-related lymphadenopathy with an emphasis on the morphologic spectrum. Design.— We describe detailed clinical and pathologic findings along with the literature review. We focus on the differential diagnosis between DRESS lymphadenopathy and angioimmunoblastic T-cell lymphoma (AITL). Results.— There were 4 men and 1 woman with a mean age of 41 years (range, 23–59 years). One patient (20%) died. Three lymph node biopsy specimens showed a pattern reminiscent of AITL (AITL-like pattern) and 2 cases showed necrotizing lymphadenitis (Kikuchi-like pattern), associated with vasculitis in 1 case. The AITL-like morphology of DRESS-related lymphadenopathy may be difficult to distinguish from genuine AITL. The clinical information is important for differential diagnosis, including history of drug exposure, age, and the rarity or absence of AITL-associated manifestations such as hemolytic anemia and hypergammaglobulinemia. Molecular analysis of the T-cell receptor genes is helpful, typically revealing a polyclonal pattern in DRESS-related lymphadenopathy. Conclusions.— In the literature, 4 histologic patterns of DRESS lymphadenopathy have been described: reactive lymphoid hyperplasia, necrotizing lymphadenitis, Hodgkin lymphoma–like, and AITL-like. These patterns, particularly those that resemble lymphoma, highlight the importance of correct diagnosis to avoid unnecessary therapies.

scholarly journals Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1757-1757
Author(s):  
Kalpana Parvathaneni ◽  
Kyabeth Toress-Rodriguez ◽  
Wenzhao Meng ◽  
James Knox ◽  
Xiaoming Xu ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Board Of Directors ◽  
T Cell Activation ◽  
Research Funding ◽  
Cell Activation ◽  
Cd4 T Cell ◽  
Advisory Committees ◽  
Cell Immunity ◽  
T Cell Immune Responses

Abstract Abstract Background: The two FDA approved mRNA-based SARS-CoV2 vaccines have shown >90% efficacy at preventing COVID and eliciting protective immunity in nearly all healthy individuals. However, the extent of vaccine induced antibody and T cell immunity in immunocompromised patients is not well known. Our study objective is to determine if patients with hematologic malignancies treated with B-cell targeting chimeric antigen receptor (CAR) T cell therapies can mount antibody and T cell immune responses to SARS-CoV2 vaccines. A prospective single-center study to evaluate the SARS-CoV2 immune responses in immunocompromised individuals (COVAX Study) was initiated at University of Pennsylvania following the IRB guidelines. The study enrolled 8 healthy adults,12 patients are in remission after treatment (average of 40.6 months) with CART cells targeting either CD19 or CD19+CD22 and received both doses of SARS-CoV2 vaccine. Methods and Results: Serology to SARS-CoV2 spike-receptor binding domain (RBD) IgG, RBD-IgA, RBD-IgM and spike-specific T cell responses were measured prior to vaccination and serially up to 28 days after booster vaccination. RBD-IgG and RBD-IgA were detected in 8/8 and 7/8 healthy subjects compared to 5/12 and 2/12 CART patients, respectively (Figure A). In the CART cohort, several patients who demonstrated an induction of RBD-IgG (57.2/uL +/- 20.2) compared to those who were RBD-IgG-negative (9/uL +/- 10.1, ANOVA with multiple comparisons test p=0.017) have higher level of circulating B cells. No association was found with time since CART infusion, age, disease type, or vaccine manufacturer. All 8 healthy subjects demonstrated induction of SARS-Cov2 spike-specific CD4 + T cell immunity compared to 7 out of 11 CART patients (Figure B). RBD-IgG responses were not correlated with CD4 + T cell activation (Pearson correlation, R=0.21, p=0.53). Indeed, 3 CART patients demonstrated robust CD4 + T cell activation despite absence of antibody induction. Overall, 8/12 CART patients demonstrated induction of either or both humoral and T cell immune responses. Conclusions: We show that immune responses to SARS-CoV2 mRNA vaccines are induced in majority of patients who have been treated with CART therapies targeting B-cell lineage antigens. Induction of vaccine-specific antibody was strongly associated with the level of circulating B cells. However, in CART cohort patients despite severe humoral immune deficiency, strong CD4 + T cell responses were observed suggestive of a sufficient protective immunity. Figure 1 Figure 1. Disclosures Frey: Novartis: Research Funding; Sana Biotechnology: Consultancy; Kite Pharma: Consultancy; Syndax Pharmaceuticals: Consultancy. Garfall: Amgen: Honoraria; CRISPR Therapeutics: Research Funding; GlaxoSmithKline: Honoraria; Janssen: Honoraria, Research Funding; Novartis: Research Funding; Tmunity: Research Funding. Porter: American Society for Transplantation and Cellular Therapy: Honoraria; Genentech: Current equity holder in publicly-traded company, Ended employment in the past 24 months; ASH: Membership on an entity's Board of Directors or advisory committees; DeCart: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Membership on an entity's Board of Directors or advisory committees; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Tmunity: Patents & Royalties; Wiley and Sons Publishing: Honoraria. June: AC Immune, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, Ziopharm: Consultancy; Tmunity, DeCART, BluesphereBio, Carisma, Cellares, Celldex, Cabaletta, Poseida, Verismo, Ziopharm: Current equity holder in publicly-traded company; Novartis: Patents & Royalties.

Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

2009 ◽  
Vol 9 (13-14) ◽  
pp. 1530-1539 ◽  
Author(s):  
Jae Yeo Park ◽  
Min Ja Jang ◽  
Yoon Hee Chung ◽  
Kyung Yong Kim ◽  
Sung Su Kim ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Cd40 Ligand ◽  
Cd4 T Cell ◽  
T Cell Immune Responses

The regulation of CD4+ T cell immune responses toward Th2 cell development by prostaglandin E2

2011 ◽  
Vol 11 (10) ◽  
pp. 1599-1605 ◽  
Author(s):  
Yu-Shi Bao ◽  
Ping Zhang ◽  
Ru-Juan Xie ◽  
Mei Wang ◽  
Zhi-Yong Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Prostaglandin E2 ◽  
Cell Development ◽  
Cd4 T Cell ◽  
Th2 Cell ◽  
T Cell Immune Responses
Sign in / Sign up

Export Citation Format

Share Document